Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention

Current Pharmaceutical Design

Volumn 14, Issue 12, 2008, Pages 1197-1204

  Huston, S A ^a   Hawkins, D ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b California Northstate College of Pharmacy   (United States)

Author keywords

ACS; Anticoagulant; Bivalirudin; Cost effective; LMWH; PCI; Pharmacoeconomic; UFH

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; NADROPARIN; PLACEBO; TENECTEPLASE; TICLOPIDINE; WARFARIN; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; CORONARY STENT; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL COST; HUMAN; LENGTH OF STAY; MEDICAL PRACTICE; NON ST SEGMENT ELEVATION HEART INFARCTION; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ST SEGMENT ELEVATION HEART INFARCTION; STANDARD; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; DRUG ANTAGONISM; ECONOMICS; STENT;

ACUTE CORONARY SYNDROME; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DRUG COSTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; STENTS;

EID: 47149103286     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784246162     Document Type: Review

References (42)

1. Pizzi LT, Lofland JH. Economic evaluation in U.S. health care: principles and applications. Sudbury, Mass: Jones and Barlett Publishers 2006.
2. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press 1997.
3. Hollenbeig N, Testa M, Williams G. Quality of life as a therapeutic end-poInt An analysis of therapeutic trials in hypertension. Drug Saf 1991; 6(2): 83-93.
4. Berger M, Bingefors K, Hedblom E, Pashos C, Torrance G, Eds. Health care cost, quality, and outcomes. Ispor book of terms. USA: International Society for Pharmacoeconomics and Outcomes Research 2003.
5. Lee J, McLaughlin-Miley C, Chatterton ML. Cost-effectiveness analysis. In: Grauer DW, Lee J, Odom,TD, Osterhaus JT, Sanchez LA, Touchette DR, Eds. Pharmacoeconomics and outcomes: Applications for patient care. 2nd Ed, Kansas: American College of Clinical Pharmacy 2003.
6. Osterhaus JT, Boyer JG. Investigating the outcomes research question. In: Grauer D, Lee J, Odom TD, Osterhaus J, Sanchez L, Touchette DR Eds. Pharmacoeconomics and outcomes: Applications for patient care. 2nd ed. Kansas: American College of Clinical Pharmacy 2003.
7. O'Brien BJ, Willan A, Blackhouse G, Goerce R, Cohen M, Goodman S. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada? Am Heart J 2000; 139(3): 423-9.
8. Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: A Canadian hospital perspective. Pharmacoeconomics 1999; 16(5 Pt 2): 533-42.
9. Detournay B, Huet X, Fagnani F, Montalescot G. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial. Pharmacoeconomics 2000; 18(1): 83-9.
10. Malhotra S, Bhargava V, Grover A, Pandhi P, Sharma Y. A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial). Int J Clin Pharmacol Themp 2001; 39: 110-5.
11. Orlewska E, BudaJ A, Tereszkowski-Kaminski D. Cost-effectiveness analysis of enoxaparin versus unfractioanted heparin ni patients with acute coronary syndrome in Poland. Pharmacoeconomics 2003; 21(10): 737-48.
12. Brosa M, Rubio-Terres C, Farr I, Nadipelli V, Froufe J Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in the secondary prevention of acute coronary syndrome. Pharmacoeconomics 2002; 20(14): 979-97.
13. Mark D. When innovative therapies make economic sense: Economic analysis of enoxaparin versus unfractionated heparin in the ESSENCE trial: An overview Can J Cardiol 1998; 14(suppl. E): 24E-7E.
14. Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc; Disord 2001; 1: 2.
15. Cohen M, Demers C, Gurfinkle E, Turpie A, Frommell G, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J M 1997; 337: 447-52.
16. Antman E, McCabe C, Gurfinkel E Turpie A, Bernink P, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial inflarction: Results from the Thrombolysis in myocardial inflarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
17. Smith SJ, Feldman T, Hirshfeld JJ, Jacobs A, Kern M, King III SB, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Comrruttee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: E166-286.
18. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes managed with an intended early invasive strategy. JAMA 2004; 292: 45-54.
19. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie A, et al. Comparison of low-molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: Fragmin in unstable coronarya rter disease study (FRIC). Circulation 1997; 96: 61-8.
20. The FRAXIS Study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (Fraxiparine in Ischaemic Syndrome).. Eur Heart J 1999; 20: 1553-62.
21. Janzon M, Levin LA, Swahn E. Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: Results from the FRISC II trial. Heart 2003; 89(3): 287-92.
22. Padma P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, et al. Economic analysis of the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction. Am Heart J 2005; 149: 637-44.
23. Anderson HV, Shaw RE, Brindis RG, Hewitt K, Krone RJ, Block PC, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology- National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002; 39: 1096-103.
24. Ulrich MR, Brock DM, Ziskind AA. Analysis of trends in coronary artery bypass grafting and percutanecus coronary intervention rates in Washington state from 1987 to 2001. Am J Cardiol 2003; 92(7): 836-9
25. Mandelzweig L, Battier A, Boyko V, Bueno H, Danchin N, Filippatos G, et al. The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACs in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006; 27(19): 2285-93.
26. Weaver W, Simes R, Betriu A, Grines C, ZiJIstra F, Garcia E, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial inforation: A quantitative review. JAMA 1997; 278: 2093-8.
27. Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Henderson WG, et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation, 2006; 114(12): 1251-7.
28. FDA. Bivalirudin Approval History: Letter dated 6/13/2005. In: Administration FaD, ed. 2005.
29. Milkovich G, Gibson G. Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60(14(S3)): S15-21.
30. Iauer M, Karweit J, Cascade E, Lin N, Topol E. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995-1997. Am J Cardiol 2002; 89: 924-9.
31. Mark D, Talley J, Topol E, Bowman L, Lam L, Anderson K, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of iscehmic complications of high-risk coronary angioplasty. EPIC investigators. Circulation 1996; 94: 629-35.
32. Ellis SG, Miller DP, Brown KJ, Omoigui N, Howell G, Kutner M, et al. In-hospital costs of percutaneous coronary revascularization: critical determinants and implications. Circulation 1995; 92: 741-7.
33. Rothman MT. Drug insight: Bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Nat Clin Pract Cardiovasc Med 2005; 2(9): 465-74.
34. Compton A. A practical cost analysis of bivalirudin. Pharmacotherapy 2002; 22(6 Pt 2): 119S-27S.
35. Bittl J, Chaitman B, Feit F, Kimball W, Topol E. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: Final reanalysis of the bivalirudin angioplasty study. Am Heart J 2001; 142: 952-9.
36. Lincoff AM, Kleiman NS, Kottke-Marchant K, Maierson ES, Maresh KR, Wolski KE, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143(5): 847-53.
37. Lincoff AM. Pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIa blockade: Results of the REPLACE 1 Trial [abstr]. J Am Coll Cardiol 2002; 39 (suppl): 16A.
38. Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol 2004; 44(9): 1792-800.
39. Summers KM, Holdford DA, Crouch MA. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention. Pharmacotherapy 2006; 26(5): 609-18.
40. Bosanquet N, Joensson B, Fox KA. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors - In the management of acute coronary syndromes. Pharmacoeconomics 2003; 21: 1135-52.
41. Weintraub WS, Barnett P, Chen S, Hartigan P, Casperson P, O'Rourke R, et al. Economics methods in the clinical outcomes utilizing percutaneous coronary revascularization and aggressive guideline-driven drug evaluation (COURAGE) trial. Am Heart J 2006; 151(6): 1180-5.
42. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, et al. REPLACE-1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events REPLACE-1 trial). Am J Cardiol 2004; 93(9): 1092-6.